Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis
Open Access
- 3 February 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Abstract
Despite progress in prostate cancer (PC) therapeutics, distant metastasis remains a major cause of morbidity and mortality from PC. Thus, there is growing recognition that preventing or delaying PC metastasis holds great potential for substantially improving patient outcomes. Here we show receptor-interacting protein kinase 2 (RIPK2) is a clinically actionable target for inhibiting PC metastasis. RIPK2 is amplified/gained in ~65% of lethal metastatic castration-resistant PC. Its overexpression is associated with disease progression and poor prognosis, and its genetic knockout substantially reduces PC metastasis. Multi-level proteomics analyses reveal that RIPK2 strongly regulates the stability and activity of c-Myc (a driver of metastasis), largely via binding to and activating mitogen-activated protein kinase kinase 7 (MKK7), which we identify as a direct c-Myc-S62 kinase. RIPK2 inhibition by preclinical and clinical drugs inactivates the noncanonical RIPK2/MKK7/c-Myc pathway and effectively impairs PC metastatic outgrowth. These results support targeting RIPK2 signaling to extend metastasis-free and overall survival.Keywords
All Related Versions
Funding Information
- U.S. Department of War (W81XWH-18-1-0476)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA218526)
- Cedars-Sinai Development of Prostate Cancer Fund Cedars-Sinai Precision Health Initiative Award UCLA CTSI core voucher Award
This publication has 78 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate CancerCancer Discovery, 2012
- Discovery of Potent and Selective Covalent Inhibitors of JNKChemistry & Biology, 2012
- A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53Oncogene, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- XIAP mediates NOD signaling via interaction with RIP2Proceedings of the National Academy of Sciences, 2009
- Promoter‐specific transcriptional interference and c‐myc gene silencing by siRNAs in human cellsThe EMBO Journal, 2009
- Large‐scale mapping of human protein–protein interactions by mass spectrometryMolecular Systems Biology, 2007
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005